Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by ReCode Therapeutics ReCode Therapeutics Presents Preclinical Data from its Cystic Fibrosis Program at the 2024 North American Cystic Fibrosis Conference (NACFC) in Boston Today 9:00 EDT From ReCode Therapeutics Via Business Wire ReCode Therapeutics Doses First Patient in Phase 1b Clinical Study of RCT2100 for the Treatment of Cystic Fibrosis Today 8:30 EDT From ReCode Therapeutics Via Business Wire ReCode Therapeutics to Participate in Upcoming Investor Conferences September 25, 2024 From ReCode Therapeutics Via Business Wire ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT1100 for the Treatment of Primary Ciliary Dyskinesia June 27, 2024 From ReCode Therapeutics Via Business Wire New Article Published in Science Highlights the Potential of ReCode Therapeutics’ Systemic Lung Delivery and CFTR Gene Correction June 13, 2024 From ReCode Therapeutics Via Business Wire ReCode Therapeutics Announces Appointment of Dean J. Mitchell as Chairman of Its Board of Directors May 13, 2024 From ReCode Therapeutics Via Business Wire ReCode Therapeutics to Participate in May Conferences May 01, 2024 From ReCode Therapeutics Via Business Wire ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Study of Inhaled mRNA-Based Genetic Medicine, RCT2100, for the Treatment of Cystic Fibrosis February 21, 2024 From ReCode Therapeutics Via Business Wire ReCode Therapeutics to Participate in February Conferences February 20, 2024 From ReCode Therapeutics Via Business Wire Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis February 15, 2024 From ReCode Therapeutics Via Business Wire Tickers NTLA ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy for the Treatment of Primary Ciliary Dyskinesia January 03, 2024 From ReCode Therapeutics Via Business Wire ReCode Therapeutics to Participate in November Conferences November 10, 2023 From ReCode Therapeutics Via Business Wire ReCode Therapeutics Announces Closing of Extension to Series B Financing September 19, 2023 From ReCode Therapeutics Via Business Wire ReCode Therapeutics to Present at September Investor Conferences September 07, 2023 From ReCode Therapeutics Via Business Wire ReCode Therapeutics Appoints Erica Jefferson as Senior Vice President of Corporate Affairs July 10, 2023 From ReCode Therapeutics Via Business Wire ReCode Therapeutics to Present at Jefferies Healthcare Conference June 02, 2023 From ReCode Therapeutics Via Business Wire ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development April 17, 2023 From ReCode Therapeutics Via Business Wire ReCode Therapeutics to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days March 27, 2023 From ReCode Therapeutics Via Business Wire ReCode Therapeutics to Present at BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines March 21, 2023 From ReCode Therapeutics Via Business Wire ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Trial of Novel Disease-Modifying Genetic Medicine, RCT1100 for the Treatment of Primary Ciliary Dyskinesia March 15, 2023 From ReCode Therapeutics Via Business Wire Recode Therapeutics Expands Leadership Team with Appointment of April Loui as Senior Vice President of Quality and CMC Regulatory Affairs February 01, 2023 From ReCode Therapeutics Via Business Wire ReCode Therapeutics Announces Strategic Investment from the Cystic Fibrosis Foundation to Accelerate Development of Novel mRNA Therapy January 10, 2023 From ReCode Therapeutics Via Business Wire ReCode Therapeutics Announces Strategic Collaboration with AskBio to Explore Single Vector Gene-Editing Platform January 09, 2023 From ReCode Therapeutics Via Business Wire ReCode Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference January 03, 2023 From ReCode Therapeutics Via Business Wire ReCode Therapeutics Appoints Trisha Millican to Board of Directors December 01, 2022 From ReCode Therapeutics Via Business Wire ReCode Therapeutics to Present at Upcoming Investor Conferences in 2022 November 22, 2022 From ReCode Therapeutics Via Business Wire ReCode Therapeutics Establishes Scientific Advisory Board November 14, 2022 From ReCode Therapeutics Via Business Wire ReCode Therapeutics to Participate in Upcoming November Investor Conferences November 02, 2022 From ReCode Therapeutics Via Business Wire ReCode Therapeutics to Participate in Upcoming October Investor Conferences September 29, 2022 From ReCode Therapeutics Via Business Wire ReCode Therapeutics to Present at Jefferies Cell and Genetic Medicine Summit September 22, 2022 From ReCode Therapeutics Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.